Aptamers, short structured single-stranded oligonucleotides binding at high affinity to a given target protein, are selected from large combinatorial libraries through repeated cycles of incubation of the library with the target, recovery and amplification of target-bound oligonucleotides (SELEX technology, Systematic Evolution of Ligands by EXponential enrichment). SELEX can be applied to select aptamers against a known target protein or against a specific cell phenotype, without any prior knowledge of the specific target, leading to new biomarkers discovery.
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 15 of 17
The present invention relates to the biomedical sector of the treatment of lung diseases and related symptoms. In particular, the present invention provides compositions and methods based on the use of selected polymeric biomaterials, in combination with stem cells and/or their secretome, capable of synergistically improving the development, regeneration and repair of chronic lung injuries and related symptoms.
The dramatic global health emergency due to the SARS-CoV-2 pandemic requires new diagnostic devices capable of identifying the presence of virus particles in patient biological samples. In this direction, the development of an innovative low-cost test, which provides the result within a few minutes, which is reproducible and which can reveal the direct presence of even a few viral particles, would be of fundamental importance for the monitoring and containment of the pandemic.
The present invention relates to a gamma camera for intracavitary use, which is widely used in the field of radio-guided surgery (intra-operative and laparoscopic and robotic-assisted) for the localisation of lymph nodes and tumours and/or other pathologies. The aim of the present invention is to make available an intraoperative tool able to overcome the drawbacks of the present known art.
Silicon nanowires (SiNWs) are 1D structures with diameter ranging from few tens to hundreds of nanometers and length varying from few tens of nanometers to millimiters. SiNWs are fabricated in the labs of the IMM-CNR, Rome Unit, by using bottom-up technologies such as plasma enhanced chemical vapor deposition (PECVD) at low growth temperature ((≤350°C), allowing the use of plastic and glassy substrates. Their electrical properties can be tuned by controlling the p/n doping during the growth.
INCIPIT technology allowed the implementation of a multifunctional, micro-structured and electroconductive therapeutic product to treat patients with myocardial infarction, the leading cause of death for cardiovascular disease. Current therapies (drugs, bypass, angioplasty) do not restore the functionality of damaged myocardial tissue.
Extracellular vesicles produced by teratocarcinoma cells were isolated and characterized. Functional assays on glioblastoma (GBM) cell cultures showed the inhibitory effect of these vesicles on tumor cell migration, without inducing undesirable effects such as increased cell proliferation or chemotherapy resistance.
Portable robotic device for bilateral neuromotor rehabilitation. An appropriate mechanical structure and a series of interchangeable accessories suitably designed allow the execution of various motor gestures of the upper limbs, involving different articulations and muscles. The possibility of being used with both limbs contributes to the recovery of motor coordination and facilitates the mechanism of brain plasticity. Some rotary axes the device is equipped with are motorized and sensorized.
Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.
The development of new materials with near-infrared emission (NIR, 700 – 1000 nm) represent an important target in the technological progress of innovative active components for OLED devices (including flexible ones), surveillance systems, autonomous driving, night vision sensors, fiber optic telecommunications and medical systems. In all these fields it still lacks a commercial NIR-OLED technology.
Combinations of several enzymes in a production chain are preferred to “first generation” enzymatic processes (where the "single reaction - single enzyme" principle was followed), for the synthesis of compounds with high added value starting from simple and cheap substrates. An important requirement for obtaining control in "cascade enzymatic reactions" is the ability to deliver from one biocatalyst to the next one the various intermediates, limiting as much as possible the diffusion of the latter in the solvent.
The technology refers to an innovative plasma (ionized gas) source operating at atmospheric pressure and low electric power levels. A cold plasma is produced, characterized by an ion temperature significantly lower than the electron temperature. Partial ionization of a Helium flux is induced by a time-varying electric field in between two parallel grids, both perpendicular to the flux itself.
Recently, it has been demonstrated that Raman spectroscopy can play a fundamental role in assisting the work of the anatomopathologist by allowing classification of oncological samples with practically 100% accuracy in oncological diagnosis.
This technology is based on an algorithm able to provide the probability of being asthmatic with high accuracy. This probability is based on the evaluation of respiratory function and, specifically, of forced expiratory vital capacity in the first second (FEV1), in resting conditions, and 20 minutes after administration of a bronchodilator drug.
Our team can develop low-cost ultra-flexible sensors integrated on plastic substrate for volatile organic compounds (VOCs) and gas detection. These devices combine scalable fabrication technologies, implementing active materials such as nanostructured metal oxides or stack of nanostructures decorated with metal nanoparticles, thus enabling a high sensitivity (in the range of hundreds of ppb). These devices can be applied to numerous industrial and commercial sectors and they can be embedded in systems that are more sophisticated.